BELIZATINIB

Investigational

Details

Stereochemistry	RACEMIC
Molecular Formula	C33H44FN5O3
Molecular Weight	577.7338
Optical Activity	( + / - )
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)NC(=O)[C@@H]1CC[C@@H](CC1)N2C(NC(=O)C3=CC=C(F)C=C3)=NC4=C2C=C(CN5CCC(CC5)C(C)(C)O)C=C4

InChI

InChIKey=WSTUJEXAPHIEIM-FEGDYQJNSA-N

InChI=1S/C33H44FN5O3/c1-21(2)35-30(40)24-8-12-27(13-9-24)39-29-19-22(20-38-17-15-25(16-18-38)33(3,4)42)5-14-28(29)36-32(39)37-31(41)23-6-10-26(34)11-7-23/h5-7,10-11,14,19,21,24-25,27,42H,8-9,12-13,15-18,20H2,1-4H3,(H,35,40)(H,36,37,41)/t24-,27+

HIDE SMILES / InChI

Molecular Formula	C33H44FN5O3
Molecular Weight	577.7338
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.e19005 | https://clinicaltrials.gov/ct2/show/NCT02048488

Belizatinib, also known as TSR-011, is an orally available inhibitor of both the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the tropomyosin-related kinases (TRK) TRKA, TRKB, and TRKC, with potential antineoplastic activity. Upon administration, ALK/TRK inhibitor TSR-011 binds to and inhibits both ALK and TRK kinases. The inhibition leads to disruption of ALK- and TRK-mediated signaling and impedes tumor cell growth in ALK/TRK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
ALK tyrosine kinase receptor 24 Target ID: CHEMBL4247 Sources: http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.e19005 \| https://www.ncbi.nlm.nih.gov/pubmed/22734674	Inhibitor 8504	0.7 nM [IC50]
Nerve growth factor receptor Trk-A 15 Target ID: CHEMBL2815 Sources: http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.e19005 \| http://www.selleckchem.com/products/tsr-011-belizatinib.html	Inhibitor 8504
Neurotrophic tyrosine kinase receptor type 2 14 Target ID: CHEMBL4898 Sources: http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.e19005 \| http://www.selleckchem.com/products/tsr-011-belizatinib.html	Inhibitor 8504
NT-3 growth factor receptor 9 Target ID: CHEMBL5608 Sources: http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.e19005 \| http://www.selleckchem.com/products/tsr-011-belizatinib.html	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cancer 609 Sources: https://clinicaltrials.gov/ct2/show/NCT02048488	Primary		Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
3327.36 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31217479	480 mg 1 times / day steady-state, oral dose: 480 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		BELIZATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY445419	https://www.001chemical.com/chem/search?q=DY445419
Hangzhou Yuhao Chemical Technology	YH65248
Molcore	MC445419	http://www.molcore.com/CatMC445419.html
Selleck Chemicals	S8511	http://www.selleckchem.com/search.html?searchDTO.searchParam=S8511
TargetMol	T4257	https://www.targetmol.com/search?keyword=T4257

PubMed

Title	Date	PubMed
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.	2014 Jul	25322323
The next-generation ALK inhibitors.	2015 Mar	25588040
Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.	2015 Sep-Oct	26389762

Patents

Sample Use Guides

In Vivo Use Guide

Twenty-three patients with advanced cancer have been enrolled at oral total daily doses between 30 and 480 mg.

Route of Administration: Oral

In Vitro Use Guide

TSR-011 inhibits ALK and tropomyosin-related kinase (TRK) A, B, and C receptor activity with IC50 values < 3 nM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 23:10:17 GMT 2025` Edited by `admin` on `Mon Mar 31 23:10:17 GMT 2025`
Record UNII	Z8A6022P3J
Record Status	`FAILED`
Record Version

Download

Name

Type

Language

BELIZATINIB

Official Name

English

belizatinib [INN]

Preferred Name

English

Belizatinib [WHO-DD]

Common Name

English

BENZAMIDE, 4-FLUORO-N-(6-((4-(1-HYDROXY-1-METHYLETHYL)-1-PIPERIDINYL)METHYL)-1-(CIS-4-(((1-METHYLETHYL)AMINO)CARBONYL)CYCLOHEXYL)-1H-BENZIMIDAZOL-2-YL)-

Systematic Name

English

BENZAMIDE, N-(1,3-DIHYDRO-6-((4-(1-HYDROXY-1-METHYLETHYL)-1-PIPERIDINYL)METHYL)-1-(CIS-4-(((1-METHYLETHYL)AMINO)CARBONYL)CYCLOHEXYL)-2H-BENZIMIDAZOL-2-YLIDENE)-4-FLUORO-, (N(E))-

Systematic Name

English

Code System Code Type Description

PUBCHEM

57345941